Release date: 2007-12-03
Understanding Common Fusion Gene Transcript Levels in Newly Diagnosed Leukemia Patients Fusion gene transcripts vary significantly among different types of leukemia and even among individuals. Measuring the transcript levels of these genes in newly diagnosed patients is crucial not only for monitoring minimal residual disease and evaluating treatment effectiveness, but also for enabling standardized data comparison across laboratories. Leukemia, often referred to as "blood cancer," is a type of malignant hematological disorder characterized by the uncontrolled proliferation of abnormal blood cells in the bone marrow or other hematopoietic tissues. These cells can spread throughout the body, affecting organ function and causing various symptoms. A study published in the July issue of the Chinese Journal of Hematology examined fusion gene transcript levels in 195 leukemia patients using TaqMan probe-based real-time quantitative RT-PCR (RQ-PCR). The research included cases of chronic myeloid leukemia (CML-CP), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML), with specific focus on M-bcr-abl, m-bcr-abl, TEL-AML1, AML1-ETO, PML-RARα, and CBFβ-MYH11 fusion genes. The transcript levels were normalized against the internal reference gene, ABL, and expressed as a percentage. The study found that M-bcr-abl transcript levels were similar in both bone marrow and peripheral blood of CML-CP patients, with median values of 30% and 35%, respectively (P > 0.05). In ALL patients, M-bcr-abl and m-bcr-abl levels were comparable (64% vs. 54%), but higher than in CML-CP patients (P < 0.001). TEL-AML1 transcript levels in ALL were notably high at 228%. In AML patients, AML1-ETO levels were significantly higher than those of CBFβ-MYH11 and PML-RARα (388% vs. 145% vs. 47%). Additionally, CBFβ-MYH11 was more prevalent than PML-RARα. The study also noted differences among subtypes of PML-RARα, with L-type being lower than S-type (45% vs. 55%, P = 0.04). These findings highlight the variability in fusion gene transcript levels among newly diagnosed leukemia patients, emphasizing the importance of individualized assessments. Understanding these differences helps clinicians better interpret results, monitor disease progression, and tailor treatments accordingly. This kind of detailed analysis is essential for improving diagnostic accuracy and ensuring consistent, reliable outcomes across different medical settings. ——Midi Medical Network
Cosmetic Injection,Disposable Injection Needles,Sterile Roller Needle,Cosmetic Threads
Changzhou Timerein Biotechnology Co. , Ltd. , https://www.timereinbiotech.com